• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Novel pill-only regimens effective against hepatitis C [COSMOS and HALLMARK-DUAL study]

byXiaozhou Liu
July 28, 2014
in Chronic Disease, Gastroenterology, Infectious Disease, Oncology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. [COSMOS study]: Simeprevir plus sofosbuvir achieved high sustained virological response 12 weeks after stopping treatment (SVR12) in patients with chronic HCV genotype 1 infections. 

2. [HALLMARK-DUAL study]: Daclatasvir plus asunaprevir achieved high SVR12 in patients with chronic HCV genotype 1b infections. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Hepatitis C infection is associated with significant mortality and morbidity – of the approximately 5,000 liver transplants performed in the US each year, at least 40% are attributable to chronic hepatitis C infections. Results of two randomized-controlled trials involving novel pill-only regimens were reported in Lancet on the World Hepatitis Day: in the COSMOS study, simeprevir plus sofosbuvir was shown to be highly effective against chronic HCV genotype 1 infections, with SVR12 over 90%. The regimen was well tolerated with serious adverse events rate of 2%. In the HALLMARK-DUAL study, daclatasvir plus asunaprevir was shown to be effective against chronic HCV genotype 1b infections, with SVR12 of 90% in treatment-naive patients. The regimen was well tolerated with serious adverse events rate of 6%. Both trials were well-designed with patient randomization. The small number of participants in the COSMOS study (168 patients) may moderately limit power.

The COSMOS study was funded by Janssen.

The HALLMARK-DUAL study was funded by Bristol-Myers Squibb.

RELATED REPORTS

Machine learning model demonstrates superior screening efficiency for Hepatitis C virus carriers

#VisualAbstract: Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018

Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018

Click to read the COSMOS study, published today in The Lancet

Click to read the HALLMARK-DUAL study, published today in The Lancet

Relevant Reading: Sofosbuvir for previously untreated chronic hepatitis C infection

In-Depth [randomized controlled trials]: The COSMOS study was a randomized controlled trial involving 167 patients. Patients were divided into 2 cohorts: previous non-responders with METAVIR scores F0-F2 (cohort 1) and previous non-responders and treatment-naive patients with METAVIR scores F3-F4 (cohort 2). Patients were randomized to 4 groups in a 2:2:1:1 ratio: simeprevir and sofosbuvir with (group 1) or without (group 2) ribavirin for 24 weeks, or simeprevir and sofosbuvir with (group 3) or without (group 4) ribavirin for 12 weeks. The primary endpoint was sustained virological response 12 weeks after treatment (SVR12). SVR12 rate was 90% (95% confidence interval [CI], 81-96) for cohort 1 and 94% (95% CI, 87-98) for cohort 2. Subgroup analyses did not demonstrate an SVR12 advantage for the longer treatment duration – SVR12 was 94% after 12 weeks of treatment and 91% after 24 weeks of treatment. There was no on-treatment virological failure. In safety analyses, the rate of discontinuation due to adverse events was 2% (4 patients). The most common adverse events were fatigue (31%), headache (20%) and nausea (16%).

The HALLMARK-DUAL study was a phase 3 randomized controlled trial. Treatment-naive patients (n=307) were randomized in a 2:1 ratio to receive daclatasvir plus asunaprevir or placebo for 12 weeks. There were an additional 205 non-responders and 235 ineligible/intolerant patients. Non-responders and ineligible/intolerant patients were given open-label daclatasvir plus asunaprevir for 24 weeks as they generally had more advanced disease. The primary endpoints were SVR12 rates for the treatment-naive patients and non-responders. SVR12 rates were 90% (95% CI, 85-94) in the treatment-naive cohort, 82% (95% CI, 77-87) in the non-responder cohort, and 82% (95% CI, 77-87) in the ineligible/intolerant cohort. The SVR12 rates were similar for patients with (84%) or without (85%) cirrhosis. HCV RNA reductions from baseline were rapid and sustained with 4.8-5.0 log­10 IU/mL reduction at week 2 before becoming undetectable at week 4 in 83% of treatment-naive patients. In safety analyses, the most common adverse events were headache, fatigue, diarrhea, nausea, and asthenia. Rate of serious adverse events on treatment was 6% (39 patients). Rates of overall adverse events were similar in treatment-naive patients receiving daclatasvir plus asunaprevir or placebo.

More from this author: New dengue fever vaccine effective in phase 3 trial, Insulin pumps more effective than multiple daily injections in type II diabetics [OpT2mise trial], Heart attack hospitalization rate in China quadruples from 2001-2011, Vitamin D supplementation does not reduce risk of falls, ¹⁸F-FDG PET brain imaging could predict recovery in vegetative patients

Image: CC/Wiki

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: asunaprevirDaclatasvirhepatitis CSimeprevirsofosbuvir
Previous Post

Impaired brain growth in preterm infants linked with delayed cognitive development

Next Post

AAP updates meningococcal vaccine recommendations

RelatedReports

Study lends support for interferon-free treatment of hepatitis C
2 Minute Medicine

Machine learning model demonstrates superior screening efficiency for Hepatitis C virus carriers

November 29, 2024
#VisualAbstract: Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018
StudyGraphics

#VisualAbstract: Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018

September 7, 2023
Screening insufficient for newborns exposed to hepatitis C virus
Gastroenterology

Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018

August 31, 2023
Screening insufficient for newborns exposed to hepatitis C virus
Chronic Disease

Uptake of hepatitis C treatment in people who inject drugs associated with decreased liver disease

July 26, 2022
Next Post
Pro-vaccine messages not associated with increased vaccination intent

AAP updates meningococcal vaccine recommendations

Malarial transmission substantially reduced in endemic Africa

2 Minute Medicine Rewind July 20 – July 27, 2014

Conjugated equine estrogens may elevate risk of venous thrombosis

Hormone therapy may not prevent atherosclerosis in menopausal women

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Oral semaglutide reduces cardiovascular event rates in high-risk patients
  • Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke
  • Hypotension- and hypertension-avoidance strategies may yield similar neurocognitive outcomes following noncardiac surgery
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.